Alzheimer’s is a progressive disease of the brain. Brian cells die over a period of several years, and symptoms progress from mild to severe.  Alzheimer’s is one of the leading causes of death in the U.S., and affects over 5 million Americans.

It has been over a decade since the FDA has approved any new medications for the treatment of Alzheimer’s.  Clinical research is currently underway in New London at CCRstudies, testing an investigational add-on medication. The team of investigators includes Laurence Radin, MD, Edward McDermott, Jr., MD, and Andrea Stewart, APRN.   This medication is taken in conjunction with the study patients current dosage of Aricept (Donepezil.)  The investigational medication is designed to improve thinking, memory, reasoning and cognition.  It is the Phase 3 of the clinical trial process.

Those interested in learning more about the Alzheimer’s study underway in New London can contact a member of the CCRstudies team at (860)443-4567, or click on this link for further details  https://www.youtube.com/watch?v=l1LgVnQ3pqU.

In addition to the study patient, caregivers play an important role in this trial.  There is no cost to participate and compensation is available for time and travel to the study patient and caregiver.